L'Oreal Q3 sales
This article was originally published in The Rose Sheet
Executive Summary
In response to rumors that Avon is on the firm's acquisition radar, CEO Jean-Paul Agon told analysts during a third-quarter sales call that he would not give a direct answer but acknowledged "we have huge opportunities in existing channels." Rumors began circulating last week that the French firm may be interested in the direct seller as a means to increase its exposure in developing markets and enter the direct-selling channel (1"The Rose Sheet" Oct. 18, 2010). In the third quarter, consumer products sales advanced 6.5%, based on comparable structure and exchange rates, to €2.4 billion, due in part to "very strong dynamism" of Maybelline, the firm says. Luxury products were up 5.7% to €1.14 billion, driven by strong sales of Yves Saint Laurent fragrances. Geographically, North America generated sales of €1.13 billion, representing growth of 3.8%, boosted by consumer and luxury products. L'Oreal is seeing its biggest gains in new markets, including Asia Pacific (up 11.5%) and Latin America (up 18.2%). Net sales in the third quarter rose 5.5% to €4.53 billion. To stay abreast of changes in marketing and the digital world, the firm has created a strategic marketing group led by Marc Menesguen, former president of Lancome
You may also be interested in...
M&A Chatter: Analysts Speculate On L'Oreal/Avon, P&G/Beiersdorf Deals
In the wake of Unilever's $3.7 billion acquisition of Alberto Culver, whispers of similar deals have rippled through the personal-care industry, including a possible L'Oreal bid for direct seller Avon
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.